Search for Brain Metastatic Prognostic Markers in Various Solid Tumors

Group Sylvie Rottey

Project 3

Description

In a previous multicenter retrospective trial, it was demonstrated that a novel developed brain metastatic score, named CERENAL, had prognostic value in brain metastatic renal cell carcinoma patients treated with targeted agents. This could however also be the case in patients diagnosed with brain metastases from other primary tumor sites. In this retrospective study, we will therefore evaluate the prognostic value of the CERENAL score in brain metastatic patients focusing primarily on breast cancer, lung cancer and colorectal carcinoma.

Funding Ageny

text

Contact

Sylvie Rottey; MD, PhD (Medical Oncology – Ghent University Hospital)
Piet Ost; MD; PhD (Radiotherapy – Ghent University Hospital)
Tijl Vermassen; PhD (Medical Oncology – Ghent University Hospital)